


## TUL01101

<b>Cat. No.:</b>	HY-152080
<b>CAS No.:</b>	2411222-97-2
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>25</sub> F <sub>2</sub> N <sub>5</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	429.46
<b>Target:</b>	JAK
<b>Pathway:</b>	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC <sub>50</sub> s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis <sup>[1]</sup> .											
<b>IC<sub>50</sub> &amp; Target</b>	JAK1 3 nM (IC <sub>50</sub> )	JAK2 37 nM (IC <sub>50</sub> )	JAK3 1517 nM (IC <sub>50</sub> )	Tyk2 36 nM (IC <sub>50</sub> )								
<b>In Vitro</b>	TUL01101 (pretreatment for 1 h) inhibits cytokine-induced pSTAT in human whole blood assay <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.											
<b>In Vivo</b>	<p>TUL01101 (1-30 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in the rat adjuvant-induced arthritis (AIA) model<sup>[1]</sup>.</p> <p>TUL01101 (15 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in collagen-induced arthritis models<sup>[1]</sup>.</p> <p>TUL01101 (15 mg/kg; p.o.) exhibits T<sub>1/2</sub> of 2.01 h, C<sub>max</sub> of 5105 nM, and oral bioavailability of 38.1% in mice<sup>[1]</sup>.</p> <p>TUL01101 (10 mg/kg; p.o.) exhibits T<sub>1/2</sub> of 3.06 h, C<sub>max</sub> of 4965 nM, and oral bioavailability of 121% in rats<sup>[1]</sup>.</p> <p>TUL01101 (5 mg/kg; p.o.) exhibits T<sub>1/2</sub> of 4.49 h, C<sub>max</sub> of 2750 nM, and oral bioavailability of 106.5% in dogs<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rat adjuvant-induced arthritis (AIA) model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 3, 10, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally administered twice daily for 14 days</td> </tr> <tr> <td>Result:</td> <td>Decreased the incidence in a dose-dependent manner.</td> </tr> </table>				Animal Model:	Rat adjuvant-induced arthritis (AIA) model <sup>[1]</sup>	Dosage:	1, 3, 10, 30 mg/kg	Administration:	Orally administered twice daily for 14 days	Result:	Decreased the incidence in a dose-dependent manner.
Animal Model:	Rat adjuvant-induced arthritis (AIA) model <sup>[1]</sup>											
Dosage:	1, 3, 10, 30 mg/kg											
Administration:	Orally administered twice daily for 14 days											
Result:	Decreased the incidence in a dose-dependent manner.											

### REFERENCES

[1]. Zhou S, et, al. Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis. J Med Chem. 2022 Dec 22;65(24):16716-16740.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA